Presentation: 2.5mg/10mg/15mg/20mg rivaroxaban tablet & 1mg/ml granules for oral suspension. Indication(s): 2.5mg Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD), or symptomatic peripheral artery disease (PAD), who are at high risk of recurrent VTE during or after an acute coronary syndrome (ACS) with elevated cardiac biomarkers. Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD), or with cardiovascular risk factors, in whom there is an indication for a short-term, long-term dual antiplatelet therapy should be avoided.

Warnings & precautions: Clinical surveillance in line with anticoagulant practice is recommended throughout the treatment period. Contraindications: Do not use in patients with coagulopathy & clinically relevant bleeding risk including cirrhotic patients with Child Pugh B & C, patients on treatment with Xarelto & ASA or Xarelto & ASA plus clopidogrel/ticlopidine should only receive concomitant treatment with NSAIDs if the benefit outweighs the bleeding risk. rivaroxaban levels can be measured by calibrated quantitative anti-Factor Xa activity tests. Xarelto tablets contains lactose.

Interactions: rivaroxaban plasma concentrations; patients with moderate renal impairment coconitantly receiving other medicinal products which increase rivaroxaban plasma concentrations; in patients concomitantly receiving strong CYP3A4 inhibitors of both CYP3A4 & P-gp not recommended as clinically relevant increased rivaroxaban plasma concentrations are observed. Avoid co-administration with dornadore. Use with caution in patients concomitantly receiving SSTRs/SNDRIs due to the increased bleeding risk; use with caution in patients concomitantly receiving SSRIs/SNRIs due to a possible increased bleeding risk. Concomitant use of strong CYP3A4 inducers should be avoided unless patient is closely observed for signs & symptoms of haemorrhage for 3 weeks, unless patient is being closely monitored.

Effects on ability to drive & use machines: syncope (uncommon) & dizziness (common) were reported. Patients experiencing these effects should not drive or use machines. Undergos oedema, occult bleeding/haemorrhage from any tissue (e.g. cerebral & peripheral nervous system, anaphylactic reactions including shock, angioedema & allergic reactions (in children: common), thrombocytosis, thrombocytopenia (in children: very common), renal impairment, fever (in children: very common), eye haemorrhage, hypotension, haemoptysis, epistaxis (in children: very common), haemoptysis, gingival bleeding, GI tract haemorrhage, GI & abdominal pains, dyspepsia, nausea, constipation, diarrhoea, vomiting (in children: very common), increase in transaminases, pruritus, rash, ecchymosis, cutaneous & subcutaneous haemorrhage, pain in extremity, urogenital tract haemorrhage (menorrhagia very common in women & drowsy be d y treated for DVT, PE & prevention of recurrent skin rash; or use with caution in patients concomitantly receiving SSRIs/SNDRIs due to a possible increased bleeding risk. Concomitant use of strong CYP3A4 inducers should be avoided unless patient is closely observed for signs & symptoms of haemorrhage for 3 weeks, unless patient is being closely monitored.

Adverse events should also be reported to Bayer plc. or search for Bayer plc. 0118 206 3000. 


Xarelto® (rivaroxaban) 2.5, 10, and 15 mg film-coated tablets & rivaroxaban 2.5mg/10mg/15mg/20mg film-coated tablets & 1mg/ml granules for oral suspension

Prescribing Information (Refer to full Summary of Product Characteristics (SmPC) before prescribing)

Presentation: 2.5mg/10mg/15mg/20mg rivaroxaban tablet & 1mg/ml granules for oral suspension. Indication(s): 2.5mg Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD), or with cardiovascular risk factors, in whom there is an indication for a short-term, long-term dual antiplatelet therapy should be avoided.

Warnings & precautions: Clinical surveillance in line with anticoagulant practice is recommended throughout the treatment period. Contraindications: Do not use in patients with coagulopathy & clinically relevant bleeding risk including cirrhotic patients with Child Pugh B & C, patients on treatment with Xarelto & ASA or Xarelto & ASA plus clopidogrel/ticlopidine should only receive concomitant treatment with NSAIDs if the benefit outweighs the bleeding risk. rivaroxaban levels can be measured by calibrated quantitative anti-Factor Xa activity tests. Xarelto tablets contains lactose.

Interactions: rivaroxaban plasma concentrations; patients with moderate renal impairment coconitantly receiving other medicinal products which increase rivaroxaban plasma concentrations; in patients concomitantly receiving strong CYP3A4 inhibitors of both CYP3A4 & P-gp not recommended as clinically relevant increased rivaroxaban plasma concentrations are observed. Avoid co-administration with dornadore. Use with caution in patients concomitantly receiving SSTRs/SNDRIs due to the increased bleeding risk; use with caution in patients concomitantly receiving SSRIs/SNRIs due to a possible increased bleeding risk. Concomitant use of strong CYP3A4 inducers should be avoided unless patient is closely observed for signs & symptoms of haemorrhage for 3 weeks, unless patient is being closely monitored.

Effects on ability to drive & use machines: syncope (uncommon) & dizziness (common) were reported. Patients experiencing these effects should not drive or use machines. Undergos oedema, occult bleeding/haemorrhage from any tissue (e.g. cerebral & peripheral nervous system, anaphylactic reactions including shock, angioedema & allergic reactions (in children: common), thrombocytosis, thrombocytopenia (in children: very common), renal impairment, fever (in children: very common), eye haemorrhage, hypotension, haemoptysis, epistaxis (in children: very common), haemoptysis, gingival bleeding, GI tract haemorrhage, GI & abdominal pains, dyspepsia, nausea, constipation, diarrhoea, vomiting (in children: very common), increase in transaminases, pruritus, rash, ecchymosis, cutaneous & subcutaneous haemorrhage, pain in extremity, urogenital tract haemorrhage (menorrhagia very common in women & drowsy be d y treated for DVT, PE & prevention of recurrent skin rash; or use with caution in patients concomitantly receiving SSRIs/SNDRIs due to a possible increased bleeding risk. Concomitant use of strong CYP3A4 inducers should be avoided unless patient is closely observed for signs & symptoms of haemorrhage for 3 weeks, unless patient is being closely monitored.

Adverse events should also be reported to Bayer plc. or search for Bayer plc. 0118 206 3000. 


Xarelto® is a trademark of the Bayer Group.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events also can be reported to Bayer plc. Tel: 0118 206 3500, Fax: 0118 206 3703, Email: pvk@bayer.com.